Pathogenesis and treatment of atherosclerosis in lupus

Rheum Dis Clin North Am. 2014 Aug;40(3):475-95, viii. doi: 10.1016/j.rdc.2014.04.003. Epub 2014 Jun 10.

Abstract

The prevalence of atherosclerosis (ATH) is higher in patients with systemic lupus erythematosus (SLE) and occurs at an earlier age. The lupus-related factors that account for this increased risk are likely numerous and related to the factors described in this article. Identifying of at-risk subjects and increasing the understanding of pathogenesis of ATH in SLE is critical for improving the quality of care and improving mortality in this vulnerable population.

Keywords: Atherosclerosis; Cardiovascular diseases; Cytokine; Proinflammatory lipids; Systemic lupus erythematosus.

Publication types

  • Review

MeSH terms

  • Age Factors
  • Atherosclerosis* / complications
  • Atherosclerosis* / epidemiology
  • Atherosclerosis* / metabolism
  • Atherosclerosis* / prevention & control
  • Biomarkers / metabolism
  • Cardiovascular Diseases* / epidemiology
  • Cardiovascular Diseases* / etiology
  • Cardiovascular Diseases* / prevention & control
  • Cytokines / metabolism*
  • Disease Management
  • Humans
  • Lipid Metabolism*
  • Lupus Erythematosus, Systemic* / complications
  • Lupus Erythematosus, Systemic* / epidemiology
  • Lupus Erythematosus, Systemic* / metabolism
  • Lupus Erythematosus, Systemic* / therapy
  • Outcome Assessment, Health Care
  • Prevalence
  • Risk Assessment / methods
  • Risk Factors

Substances

  • Biomarkers
  • Cytokines